Company Overview and News

1
AJX / Great Ajax Corp. DEFINITIVE PROXY STATEMENT

2018-04-06 sec.gov
tv490543-def14a - none - 1.9951938s TABLE OF CONTENTS
Upvote Downvote

3
Quarterly Performance Review Ending February 2018

2018-03-10 seekingalpha
I believe in transparency when doing equity research. Therefore, I regularly publish performance of every ticker that I wrote an article on alongside the initial thesis.
Upvote Downvote

 
Great Ajax Corp 2017 Q4 - Results - Earnings Call Slides

2018-03-08 seekingalpha
The following slide deck was published by Great Ajax Corp in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
Great Ajax's (AJX) CEO Lawrence Mendelsohn on Q4 2017 Results - Earnings Call Transcript

2018-03-07 seekingalpha
Good afternoon and welcome to the Great Ajax Corporation Fourth Quarter 2017 Financial Results Conference Call. All participants will be listen-only mode. [Operator Instructions]. Please note, this event is being recorded.
Upvote Downvote

 
Top 50 Real Estate Stocks: Yields To 18.5%; Gains To 45.25% By March 2019

2018-03-06 seekingalpha
GEO Group led by net gains and estimated price growth as Chinese Estates led by yield. Top ten gainers, GOV, SLD, AJX, SNH, CHMI, CHMI, GOOD, WSR, CIO, SIR, &.
Upvote Downvote

 
AJX / Great Ajax Corp. ER

2018-02-23 sec.gov
Mail Stop 3233 November 14, 2017 Via E-mail Mary Doyle Chief Financial Officer Great Ajax Corp. 9400 SW Beaverton-Hillsdale Hwy. Suite 131 Beaverton, OR 97005 Re: Great Ajax Corp. Form 10-K Filed March 2, 2017 File No. 001-36844 Dear Ms. Doyle: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. In some of our comments, we may ask you to provide us with information so we may better unders
Upvote Downvote

 
AJX / Great Ajax Corp. ESP

2018-02-23 sec.gov
      November 22, 2017    VIA EDGAR     Robert F. Telewicz, Jr., Accounting Branch Chief Office of Real Estate and Commodities Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549      Re: Great Ajax Corp.     Form 10-K for Year Ended December 31, 2016     Filed March 2, 2017     File No. 001-36844   Dear Mr. Telewicz:   This letter responds to your letter, dated November 14, 2017 (the “Letter”), to Mary Doyle, Chief Financial Officer of Great Aj
Upvote Downvote

 
AJX / Great Ajax Corp. ER

2018-02-23 sec.gov
Mail Stop 3233 January 10, 2018 Via E-mail Mary Doyle Chief Financial Officer Great Ajax Corp. 9400 SW Beaverton-Hillsdale Hwy. Suite 131 Beaverton, OR 97005 Re: Great Ajax Corp. Form 10-K Filed March 2, 2017 Response Dated November 22, 2017 File No. 001-36844 Dear Ms. Doyle: We have reviewed your response to our comments and have the following additional comment. In our comment, we ask you to provide us with information so we may better understand your disclosure
Upvote Downvote

 
AJX / Great Ajax Corp. ESP

2018-02-23 sec.gov
   January 16, 2018    VIA EDGAR     Robert F. Telewicz, Jr., Accounting Branch Chief Office of Real Estate and Commodities Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549      Re: Great Ajax Corp.     Form 10-K     Filed March 2, 2017     Initial Response Letter, Dated November 22, 2017     File No. 001-36844    Dear Mr. Telewicz:   This letter is submitted in response to your letter, dated January 10, 2018 (the “Letter”), to Ms.
Upvote Downvote

 
AJX / Great Ajax Corp. ER

2018-02-23 sec.gov
Mail Stop 3233 January 24, 2018 Via E-mail Mary Doyle Chief Financial Officer Great Ajax Corp. 9400 SW Beaverton-Hillsdale Hwy. Suite 131 Beaverton, OR 97005 Re: Great Ajax Corp. Form 10-K Filed March 2, 2017 File No. 001-36844 Dear Ms. Doyle: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of act
Upvote Downvote

 
AJX / Great Ajax Corp. FORM 8-K (Current Report)

2018-02-21 sec.gov
        UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): February 21, 2018   GREAT AJAX CORP. (Exact name of registrant as specified in charter)   Maryland   001 36844   47 1271842 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
AJX / Great Ajax Corp. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Great Ajax Corp (Name of Issuer) REIT (Title of Class of Securities) 38983D300 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cove
Upvote Downvote

 
AJX / Great Ajax Corp. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Great Ajax Corp (Name of Issuer) REIT (Title of Class of Securities) 38983D300 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cove
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 38983D300